- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03329664
Autologous Killer Cell Therapy in Colon Cancer Patients
March 11, 2021 updated by: Naser Ahmadbeigi, Sabz Biomedicals
Safety and Efficacy of ex Vivo Activated and Expanded Autologous Cytokine-induced Killer Cells for Colon Cancer Patients
This study aims to evaluate the safety and efficacy of activated and expanded autologous cytokine-killer cells in controlling disease recurrence in colon cancer patients with liver metastasis.
20 patients with confirmed stage IV colon carcinoma with metastasis will be assigned into two groups.
Patients in both groups will receive the same therapeutic regimen as usual.
Patients in one group additionally will be treated with a single infusion of autologous killer cells that had been previously prepared from peripheral blood.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Naser Ahmadbeigi, Ph.D
- Phone Number: +9821-82415103
- Email: n-ahmadbeigi@sina.tums.ac.ir
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Recruiting
- Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences
-
Contact:
- Naser Ahmadbeigi, Phd
- Phone Number: 09129155066
- Email: ahmadbeigi28@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with histologically confirmed colorectal cancer at stage IV
- ECOG performance status 0-2
- Adequate cardiac/renal/hepatic function
- Adequate bone marrow function (blood cell count)
Exclusion Criteria:
- Patients that have received prior chemotherapy or immune cell therapy
- Patients that have previously participated in another clinical trial
- History of positive test result for HIV, HBV, HCV, HTLV-1, syphilis
- Presence of Active infections
- Patients with immunodeficiencies, autoimmunities, or severe allergies
- Receiving immunosuppressive regimens
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CIK Intervention plus routine treatment
Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
|
Immune-cell therapy with CIK cells
Other Names:
Routine treatments for colon cancer patients according to their stage
|
ACTIVE_COMPARATOR: Control
Patients who receive routine treatments only (chemotherapy, radiation therapy)
|
Routine treatments for colon cancer patients according to their stage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of administering CIK cells plus chemotherapy
Time Frame: one month post infusion
|
Patients will be continually assessed for unexpected adverse events or unexpected early mortality 30 days post infusion
|
one month post infusion
|
Progression-free Survival (PFS)
Time Frame: 2 years
|
The time from treatment initiation day to first documented progressive disease or death due to disease.
|
2 years
|
Time to progression (TTP)
Time Frame: 2 years
|
the time from randomization until cancer progression, not including death.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 2 years
|
The length of time that the patients are still alive at a defined period of time after treatment
|
2 years
|
Patient quality of life
Time Frame: each 3 months for 2 years
|
Quality of patients enrolling in the study assessed using EORTC-CR29 questionnaire
|
each 3 months for 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Naser Ahmadbeigi, Ph.D, Cell-based Therapies Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 9, 2020
Primary Completion (ANTICIPATED)
September 1, 2021
Study Completion (ANTICIPATED)
January 1, 2022
Study Registration Dates
First Submitted
October 30, 2017
First Submitted That Met QC Criteria
October 30, 2017
First Posted (ACTUAL)
November 6, 2017
Study Record Updates
Last Update Posted (ACTUAL)
March 15, 2021
Last Update Submitted That Met QC Criteria
March 11, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Autologous Killer cell therapy
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer Stage IV
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Adenocarcinoma | Advanced Colon Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage III Colon Cancer | Stage III Rectal CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditionsUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditionsUnited States, Puerto Rico
-
Ohio State University Comprehensive Cancer CenterCompletedRecurrent Colon Cancer | Recurrent Rectal Cancer | Stage IV A Bladder Cancer | Stage IV A Rectal Cancer | Stage IV B Colon Cancer | Stage IV B Rectal CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC... and other conditionsUnited States
-
Howard S. Hochster, MDRecruitingStage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon CarcinomaUnited States
-
M.D. Anderson Cancer CenterBristol-Myers Squibb; Syntrix Biosystems, Inc.RecruitingMetastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditionsUnited States
Clinical Trials on Cytokine-induced killer cell
-
Alliancells-PuRui Biocience Co., Ltd.Zhongyuan Union Stem Cell Bio-engineering CorporationUnknownRenal Cell Carcinoma | Hepatocellular Carcinoma | Lung CancerChina
-
People's Hospital of GuangxiUnknownSmall Cell Lung CancerChina
-
Siriraj HospitalMahidol UniversityUnknownCholangiocarcinomaThailand
-
Robert NegrinNational Institutes of Health (NIH)UnknownMultiple Myeloma | Blood and Marrow Transplant (BMT)United States
-
The First People's Hospital of ChangzhouActive, not recruitingUrinary Bladder Neoplasms
-
The First People's Hospital of ChangzhouNot yet recruitingEsophageal Squamous Cell Carcinoma
-
Sun Yat-sen UniversityCompletedHepatocellular CarcinomaChina
-
Yanjuan ZhuUnknown
-
The First People's Hospital of ChangzhouActive, not recruiting
-
The First People's Hospital of ChangzhouActive, not recruiting